



- **Result of the votes at Theradiag's Annual and Extraordinary General Meeting**
- **Change in the composition of the Board of Directors chaired by Gérard Tobelem**
  - **The Board of Directors reaffirms its confidence in the CEO**
    - **Update regarding the HOB Biotech situation**

**Croissy-Beaubourg**, June 5, 2018, 8am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, today announces the results of the voting at its Ordinary Annual and Extraordinary General Meeting.

#### **Results of the voting at the Ordinary Annual and Extraordinary General Meeting**

The Company' Ordinary Annual and Extraordinary General Meeting was held on May 29, 2018 in the offices of the Fieldfisher law firm, 48 rue Cambon, 75001 Paris, France. The number of shares held by shareholders present or represented at the Meeting was 2,536,253, giving a quorum of 29.27%.

The results of the votes of Theradiag's shareholders at this Meeting were as follows:

	Resolution n°	Resolution	N° of votes FOR	N° of abstentions	N° of votes AGAINST	Votes	%	Result of the vote
Ordinary General Meeting	1	Approval of financial statements	1,585,315	0	1,057,066	For Against	60.00% 40.00%	Adopted
	2	Approval of consolidated accounts	1,901,125	0	741,256	For Against	71.95% 28.05%	
	3	Approval of expenses and liabilities (art. 39 CGI)	2,642,381	0	0	For Against	100.00% 0.00%	Adopted
	4	Allocation of 2017 annual income	1,900,612	0	741,769	For Against	71.93% 28.07%	
	5	Approval of regulated agreements	2,641,668	0	713	For Against	99.97% 0.03%	Adopted
	6	Renewal of Mr. Michel FINANCE as a Director	1,199,100	578,375	864,906	For Abstentions Against	45.38% 21.89% 32.73%	
	7	Renewal of Mr. Pierre MORGON as a Director	1,885,253	0	757,128	For Against	71.35% 28.65%	Adopted
	8	Renewal of Mr. Vincent FERT as a Director	1,892,563	0	749,818	For Against	71.62% 28.38%	
	9	Removal of Mr. John LI	1,318,087	0	1,324,294	For Against	49.88% 50.12%	Rejected
	10	Renewal of the Company's statutory auditors	1,897,763	0	744,618	For Against	71.82% 28.18%	
	11	Renewal of the Company's alternate statutory auditors	2,641,468	0	913	For Against	99.97% 0.03%	Adopted
	12	Setting of Board members' attendance fees	2,514,681	0	127,700	For Against	95.17% 4.83%	
	13	Share buyback	1,860,953	0	781,428	For Against	70.43% 29.57%	Adopted
Extraordinary General Meeting	14	Decision not to dissolve early	2,642,381	0	0	For Against	100.00% 0.00%	
	15	Capital increase with pre-emptive subscription rights	1,733,840	713	907,828	For Abstentions Against	65.62% 0.03% 34.36%	Rejected
	16	Capital increase without pre-emptive subscription rights via a public offering	789,609	0	1,852,772	For Against	29.88% 70.12%	
	17	Capital increase without pre-emptive subscription rights via a private placement	791,072	0	1,851,309	For Against	29.94% 70.06%	Rejected
	18	Capital increase without pre-emptive subscription rights for certain categories of beneficiaries	717,797	0	1,924,584	For Against	27.16% 72.84%	
	19	Increase in the number of shares by virtue of the 4 previous resolutions	1,617,055	0	1,025,326	For Against	61.20% 38.80%	Rejected
	20	Free share allotment	1,529,438	0	1,112,943	For Against	57.88% 42.12%	
	21	Capital increase reserved for employees	635,267	0	2,007,114	For Against	24.04% 75.96%	Rejected
	22	Setting of the global ceiling	1,737,103	0	905,278	For Against	65.74% 34.26%	
	23	Reduction in the share capital via the cancellation of shares	1,576,466	315,810	750,105	For Abstentions Against	59.66% 11.95% 28.39%	Rejected
	24	Powers to carry out formalities	2,325,858	316,523	0	For Abstentions Against	88.02% 11.98% 0.00%	
Ordinary General Meeting (resolutions tabled on HOB Biotech Group Corp. Ltd's request)	25	Removal of Mr. Michel FINANCE (Resolution that became void during the AGM)	0	0	0	For Against	- -	-
	26	Removal of Mr. Gérard TOBELEM	867,866	578,375	1,196,140	For Abstentions Against	32.84% 21.89% 45.27%	
	27	Appointment of Mrs. Sylvie BRATEL as a Director	1,449,568	4,000	1,188,813	For Abstentions Against	54.86% 0.15% 44.99%	Adopted
	28	Appointment of HOB BIOTECH as a Director (Resolution that became void during the AGM)	0	0	0	For Against	- -	

### **Change in the composition of the Board of Directors**

Following this AGM, Theradiag's Board of Directors still comprises seven members and has just one new member, Sylvie Bratel, who has declared herself to be an independent director. The composition of the Board of Directors is thus now as follows:

- Gérard Tobelem, Chairman of the Board
- Sylvie Bratel, Independent Director
- Dominique Costantini, Independent Director
- Vincent Fert, Independent Director
- John Li, Director
- Pierre Morgon, Independent Director
- Dominique Takizawa, Independent Director

After completing engineering degrees in France and the United States, in 1982 Sylvie Bratel joined Banque Nationale de Paris to work on technological innovation projects. She continued her career with the General Inspectorate and the Balance Sheet Management department before joining the Caisse des Dépôts et Consignation group in 1995, where she worked in the Competitive Banking Activities and Strategy departments. She participated in the creation of CDC-Markets before steering merger operations with Groupe Caisse d'Épargne and Groupe des Banques Populaires with the creation of Natixis. From 2009 to 2014, Sylvie Bratel was Head of Strategy for British insurance company Aviva's French subsidiary and then VP of its life insurance subsidiary Aviva Vie. Since 2014, Sylvie Bratel, independent director, has been IFA and EcoDa certified.

### **The Board of Directors reaffirms its confidence in the CEO**

At its meeting of June 4, 2018, the Board of Directors confirmed Michel Finance's mandate as CEO and reaffirmed its full and complete confidence in him.

### **Update regarding the HOB Biotech situation**

HOB Biotech's failure to comply with the terms of the 2015 contractual agreements signed by both companies has led to Theradiag being unable to distribute the agreed products in Europe or to market its reagents in China. Because of the loss suffered by Theradiag, legal proceedings have been initiated against HOB Biotech in order to obtain compensation.



### About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees.

For more information about Theradiag, please visit our website: [www.theradiag.com](http://www.theradiag.com)



#### **Theradiag**

Investor Relations

**Fabienne François**

**CFO**

Tel.: +33 (0)1 64 62 10 12  
[contact@theradiag.com](mailto:contact@theradiag.com)

#### **NewCap**

Financial Communications  
& Investor Relations

**Valentine Brouhot**

Tel.: +33 (0)1 44 71 94 94  
[theradiag@newcap.eu](mailto:theradiag@newcap.eu)

#### **Alize RP**

Press Relations

**Caroline Carmagnol**

Tel.: +33 (0)1 44 54 36 64  
[theradiag@alizerp.com](mailto:theradiag@alizerp.com)